She is a member of the Italian Association of Medical Oncology (AIOM), of the European Society for Medical Oncology (ESMO), of the American Society of Clinical Oncology (ASCO), of the European Association for the Study of the Liver (EASL), of the International Liver Cancer Association (ILCA).

She is a member of the AIOM Guidelines Writing Committee on Hepatocellular Carcinoma, of the Scientific Committee of the Italian Group for the Study of Digestive Tract Cancers (GISCAD) Foundation, of the Scientific Committee of the Suisse Liver Cancer Foundation, and of the ILCA Communication Committee. She is author of more than 100 articles published in peer-reviewed journals on the development of new treatments and biomarkers for gastrointestinal cancers. She is Associate Editor for Liver Cancer International, member of the Editorial Board of Journal of Hepatology and Scientific Reports. She is ad-hoc reviewer for several international scientific journals. She is speaker, chairman, discussant, member of the organizing and scientific committee at national and international congresses and conferences.

Lorenza Rimassa has a long-standing interest in the field of clinical and translational cancer research, and she has been involved in more than 100 clinical trials (phase 1-2-3). From 2005, she focused her interest on patients with gastrointestinal cancers, including hepatocellular carcinoma and biliary tract cancers, treated with new drugs in national and international clinical trials. From 2012, she is principal investigator, member of the steering committee, or of the data monitoring committee for national and international, multicenter, phase 1-2-3 clinical and translational trials of new drugs for gastrointestinal cancers, especially hepatocellular carcinoma and biliary tract cancers, including chemotherapy, small molecules, monoclonal antibodies, immuno-oncology drugs.